[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subjects-with-mild-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subjects-with-mild-hypertension":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":14,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100601974",false,"NCT07117474","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.","Inclusion Criteria:\n\n1. Males or infertile women aged 18-65 years (inclusive);\n2. Body mass index in the range of 19-28 kg\u002Fm2 (inclusive);\n3. Mild primary hypertension, without antihypertensive treatment, with a mean sitting systolic blood pressure ≥ 130 mmHg and ≤ 159 mmHg during screening and baseline, and a mean 24-hour ambulatory systolic blood pressure ≥ 130 mmHg during screening.\n\nExclusion Criteria:\n\n1. Abnormal daily life rhythm;\n2. Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;\n3. Secondary hypertension;\n4. Mean sitting diastolic blood pressure ≥ 100 mmHg;\n5. Orthostatic hypotension;\n6. History of type 2 diabetes mellitus or poorly controlled blood glucose;\n7. Recently received any antihypertensive medications or medications that affect blood pressure.",true,"ALL","18 Years","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects",[26],"Subjects With Mild Hypertension","RECRUITING","2025-08-04",{"date":30,"type":31},"2025-08-12","ACTUAL",{"date":33,"type":31},"2024-12-24",{"date":35,"type":20},"2025-12",{"name":37,"class":38},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",""]